Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2013

01-06-2013 | Review

Therapy of adrenal insufficiency: an update

Authors: Alberto Falorni, Viviana Minarelli, Silvia Morelli

Published in: Endocrine | Issue 3/2013

Login to get access

Abstract

Adrenal insufficiency may be caused by the destruction or altered function of the adrenal gland with a primary deficit in cortisol secretion (primary adrenal insufficiency) or by hypothalamic-pituitary pathologies determining a deficit of ACTH (secondary adrenal insufficiency). The clinical picture is determined by the glucocorticoid deficit, which may in some conditions be accompanied by a deficit of mineralcorticoids and adrenal androgens. The substitutive treatment is aimed at reducing the signs and symptoms of the disease as well as at preventing the development of an addisonian crisis, a clinical emergency characterized by hypovolemic shock. The oral substitutive treatment should attempt at mimicking the normal circadian profile of cortisol secretion, by using the lower possible doses able to guarantee an adequate quality of life to patients. The currently available hydrocortisone or cortisone acetate preparations do not allow an accurate reproduction of the physiological secretion pattern of cortisol. A novel dual-release formulation of hydrocortisone, recently approved by EMEA, represents an advancement in the optimization of the clinical management of patients with adrenal insufficiency. Future clinical trials of immunomodulation or immunoprevention will test the possibility to delay (or prevent) the autoimmune destruction of the adrenal gland in autoimmune Addison’s disease.
Literature
1.
2.
S. Ten, M. New, N. Maclaren, Clinical review 130: Addison’s disease 2001. J. Clin. Endocrinol. Metab. 86, 2909–2922 (2001)PubMedCrossRef
3.
T. Addison, On the constitutional and local effects of disease of the supra-renal capsules. 1855. Reproduced in Dr. Addison’s works. New Sydenham Soc. 36, 211–239 (1868)
4.
P. Aubourg, The expanding world of primary adrenal insufficiencies. Eur. J. Endocrinol. 137, 10–12 (1997)PubMedCrossRef
5.
S. Laureti, F. Santeusanio, A. Falorni, Recent advances in the diagnosis and therapy of primary adrenal insufficiency. Curr. Med. Chem. 2, 251–258 (2002)
6.
A.S. Mason, T.W. Meade, J.A.H. Lee, J.N. Morris, Epidemiological and clinical picture of Addison’s disease. Lancet II, 744–747 (1968)CrossRef
7.
J. Nerup, Addison’s disease—clinical studies. A report of 108 cases. Acta Endocrinol. (Copenh.) 76, 127–141 (1974)
8.
S. Laureti, L. Vecchi, F. Santeusanio, A. Falorni, Is the prevalence of Addison’s disease underestimated? J. Clin. Endocrinol. Metab. 84, 1762 (1999)PubMedCrossRef
9.
M.F. Kong, W. Jeffcoate, Eighty-six cases of Addison’s disease. Clin. Endocrinol. (Oxf.) 41, 757–761 (1994)CrossRef
10.
A.C. Willis, F.P. Vince, The prevalence of Addison’s disease in Coventry, UK. Postgrad. Med. J. 73, 286–288 (1997)PubMedCrossRef
11.
K. Løvas, E.S. Husebye, High prevalence and increasing incidence of Addison’s disease in western Norway. Clin. Endocrinol. (Oxf.) 56, 787–791 (2002)CrossRef
12.
C. Betterle, C. Dal Pra, F. Mantero, R. Zanchetta, Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 23, 327–364 (2002)PubMedCrossRef
13.
A. Falorni, A. Brozzetti, F. Calcinaro, S. Marzotti, F. Santeusanio, Recent advances in adrenal autoimmunity. Expert Rev. Clin. Endocrinol. Metab. 4, 333–348 (2009)CrossRef
14.
O. Winqvist, F.A. Karlsson, O. Kämpe, 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 339, 1559–1562 (1992)PubMedCrossRef
15.
A. Baumann-Antczak, N. Wedlock, J. Bednarek, Y. Kiso, H. Krishnan, S. Fowler, B. Rees Smith, J. Furmaniak, Autoimmune Addison’s disease and 21-hydroxylase. Lancet 340, 429–430 (1992)PubMedCrossRef
16.
J. Bednarek, J. Furmaniak, N. Wedlock, Y. Kiso, A. Baumann-Antczak, S. Fowler, H. Krishnan, J.A. Craft, B. Rees Smith, Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett. 309, 51–55 (1992)PubMedCrossRef
17.
A. Falorni, A. Nikoshkov, S. Laureti et al., High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J. Clin. Endocrinol. Metab. 80, 2752–2755 (1995)PubMedCrossRef
18.
J. Colls, C. Betterle, M. Volpato, L. Prentice, B.R. Smith, J. Furmaniak, Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin. Chem. 41, 375–380 (1995)PubMed
19.
H. Tanaka, M.S. Perez, M. Powell et al., Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J. Clin. Endocrinol. Metab. 82, 1440–1446 (1997)PubMedCrossRef
20.
R. Nigam, E. Bhatia, D. Mei, L. Yu, A. Brozzetti, G.S. Eisenbarth, A. Falorni, Low prevalence of 21-hydroxylase antibodies in idiopathic Addison’s disease from India. Clin. Endocrinol. 59, 593–598 (2003)CrossRef
21.
F. Kelestimur, The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J. Endocrinol. Invest. 27, 380–386 (2004)PubMed
22.
23.
E.R. McCabe, DAX1: increasing complexity in the roles of this novel nuclear receptor. Mol. Cell. Endocrinol. 265–266, 179–182 (2007)PubMedCrossRef
24.
J.C. Achermann, M. Ito, M. Ito, P.C. Hindmarsch, J.L. Jameson, A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat. Genet. 22, 125–126 (1999)PubMedCrossRef
25.
A.J. Clark, L. McLoughlin, A. Grossman, Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 341, 461–462 (1993)PubMedCrossRef
26.
A. Weber, T.F. Wienker, M. Jung, D. Easton, H.J. Dean, C. Heinrichs, A. Reis, A.J. Clark, Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster. Hum. Mol. Genet. 5, 2061–2066 (1996)PubMedCrossRef
27.
K. North, M.S. Korson, N. Krawiecki, J.M. Shoffner, I.A. Holm, Oxidative phosphorylation defect associated with primary adrenal insufficiency. J. Pediatrics 128, 688–692 (1996)CrossRef
28.
H.C. Andersson, J. Frentz, J.E. Martínez, C.M. Tuck-Muller, J. Bellizaire, Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. 82, 382–384 (1999)PubMedCrossRef
29.
R. Perry, O. Kecha, J. Paquette, C. Huot, G. Van Vliet, C. Deal, Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J. Clin. Endocrinol. Metab. 92, 4602–4608 (2005)
30.
C. Betterle, C. Scalici, F. Presotto et al., The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J. Endocrinol. 117, 467–475 (1988)PubMedCrossRef
31.
A. De Bellis, A. Bizzarro, R. Rossi, V.A. Paglionico, T. Criscuolo, G. Lombardi, A. Bellastella, Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J. Clin. Endocrinol. Metab. 76, 1002–1007 (1993)PubMedCrossRef
32.
C. Betterle, M. Volpato, B. Rees-Smith et al., I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J. Clin. Endocrinol. Metab. 82, 932–938 (1997)PubMedCrossRef
33.
C. Betterle, M. Volpato, B. Rees Smith, J. Furmaniak, S. Chen, R. Zanchetta, N.A. Greggio, B. Pedini, M. Boscaro, F. Presotto II, Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison’s disease. J. Clin. Endocrinol. Metab. 82, 939–942 (1997)PubMedCrossRef
34.
S. Laureti, A. De Bellis, V.I. Muccitelli et al., Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. J. Clin. Endocrinol. Metab. 83, 3507–3511 (1998)PubMedCrossRef
35.
G. Coco, C. Dal Pra, F. Presotto et al., Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J. Clin. Endocrinol. Metab. 91, 1637–1645 (2006)PubMedCrossRef
36.
B. Jacobs, C. Papewalis, M. Ehlers, M. Schott, Endocrine organs under the control of the immune system: potential implications for cellular therapies. Horm. Metab. Res. 42, 912–917 (2010)PubMedCrossRef
37.
K.I. Papadopoulos, B. Hallengren, Polyglandular autoimmune syndrome type II in patients with idiopathic Addison’s disease. Acta Endocrinol. (Copenh.) 122, 472–478 (1990)
38.
A.A. Kasperlik-Zaluska, B. Migdalska, B. Czarnocka, J. Drac-Kaniewska, E. Niegowska, W. Czech, Association of Addison’s disease with autoimmune disorders—a long-term observation of 180 patients. Postgrad. Med. J. 67, 984–987 (1991)PubMedCrossRef
39.
P.M. Zelissen, E.J. Bast, R.J. Croughs, Associated autoimmunity in Addison’s disease. J. Autoimmunity 8, 121–130 (1995)CrossRef
40.
A. La Marca, A. Brozzetti, G. Sighinolfi, S. Marzotti, A. Volpe, A. Falorni, Primary ovarian insufficiency: autoimmune causes. Curr. Opin. Obstet. Gynecol. 22, 277–282 (2010)PubMed
41.
G.S. Eisenbarth, P.A. Gottlieb, Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350, 2068–2079 (2004)PubMedCrossRef
42.
P. Peterson, J. Pitkänen, N. Sillanpää, K. Krohn, Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin. Exp. Immunol. 135, 348–357 (2004)PubMedCrossRef
43.
A. Meager, K. Visvalingam, P. Peterson, K. Möll, A. Murumägi, K. Krohn, P. Eskelin, J. Perheentupa, E. Husebye, Y. Kadota, N. Willcox, Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006)PubMedCrossRef
44.
A. Meloni, M. Furcas, F. Cetani, C. Marcocci, A. Falorni, R. Perniola, M. Pura, A.S. Bøe Wolff, E. Husebye, D. Lilic, K.R. Ryan, A.R. Gennery, A.J. Cant, M. Abinun, G.P. Spickett, P.D. Arkwright, D. Denning, C. Costigan, M. Dominguez, V. McConnell, N. Willcox, A. Meager, Autoantibodies against type I Interferons as an additional diagnostic criteria for Autoimmune Polyendocrine Syndrome type 1. J. Clin. Endocrinol. Metab. 93, 4389–4397 (2008)PubMedCrossRef
45.
A. Falorni, A. Brozzetti, D. La Torre, C. Tortoioli, G. Gambelunghe, The association of genetic polymorphisms and autoimmune Addison’s disease. Expert Rev. Clin. Immunol. 4, 441–456 (2008)PubMedCrossRef
46.
P.W. Speiser, R. Azziz, L.S. Baskin, L. Ghizzoni, T.W. Hensle, D.P. Merke, H.F. Meyer-Bahlburg, W.L. Miller, V.M. Montori, S.E. Oberfield, M. Ritzen, P.C. White, Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133–4160 (2010)PubMedCrossRef
47.
A. Nordenström, S. Ahmed, J. Jones, M. Coleman, D.A. Price, P.E. Clayton, C.M. Hall, Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm. Res. 63, 22–28 (2005)PubMedCrossRef
48.
S. Pang, M.K. Shook, Current status of neonatal screening for congenital adrenal hyperplasia. Curr. Opin. Pediatr. 9, 419–423 (1997)PubMedCrossRef
49.
B.L. Therrell, Newborn screening for congenital adrenal hyperplasia. Endocrinol. Metab. Clin. North Am. 30, 15–30 (2001)PubMedCrossRef
50.
H.J. van der Kamp, J.M. Wit, Neonatal screening for congenital adrenal hyperplasia. Eur. J. Endocrinol. 151(Suppl 3), U71–U75 (2004)PubMedCrossRef
51.
G. Reimondo, S. Bovio, B. Allasino, M. Terzolo, A. Angeli, Secondary hypoadrenalism. Pituitary 11, 147–154 (2008)PubMedCrossRef
52.
P. Caturegli, C. Newschaffer, A. Olivi, M.G. Pomper, P.C. Burger, N.R. Rose, Auutoimmune hypophysitis. Endocr. Rev. 26, 599–614 (2005)PubMedCrossRef
53.
M.S. Cooper, P.M. Stewart, Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348, 727–734 (2003)PubMedCrossRef
54.
E. Arvat, L. Di Vito, F. Lanfranco, M. Maccario, C. Baffoni, R. Rossetto, G. Aimaretti, F. Camanni, E. Ghigo, Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J. Clin. Endocrinol. Metab. 85, 3141–3146 (2000)PubMedCrossRef
55.
S. Laureti, E. Arvat, P. Candeloro, L. Di Vito, E. Ghigo, F. Santeusanio, A. Falorni, Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison’s disease. Clin. Endocrinol. (Oxf.) 53, 107–115 (2000)CrossRef
56.
S. Laureti, P. Candeloro, M.C. Aglietti, R. Giordano, E. Arvat, E. Ghigo, F. Santeusanio, A. Falorni, Dehydroepiandrosterone, 17alpha-hydroxyprogesterone and aldosterone responses to the low-dose (1 micro g) ACTH test in subjects with preclinical adrenal autoimmunity. Clin. Endocrinol. (Oxf.) 57, 677–683 (2002)CrossRef
57.
A. Falorni, S. Laureti, A. De Bellis et al., Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 89, 1598–1604 (2004)PubMedCrossRef
58.
S. Laureti, P. Aubourg, F. Calcinaro, F. Rocchiccioli, G. Casucci, G. Angeletti, P. Brunetti, Å. Lernmark, F. Santeusanio, A. Falorni, Etiological diagnosis of primary adrenal insufficiency using an original flow-chart of immune and biochemical markers. J. Clin. Endocrinol. Metab. 83, 3163–3168 (1998)PubMedCrossRef
59.
E.S. Husebye, J. Perheentupa, R. Rautemaa, O. Kämpe, Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J. Intern. Med. 265, 514–529 (2009)PubMedCrossRef
60.
A. Falorni, S. Laureti, P. Candeloro et al., Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil. Steril. 78, 270–279 (2002)PubMedCrossRef
61.
G. Reato, L. Morlin, S. Chen, J. Furmaniak, B.R. Smith, S. Masiero, M.P. Albergoni, S. Cervato, R. Zanchetta, C. Betterle, Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation. J. Clin. Endocrinol. Metab. 96, E1255–E1261 (2011)PubMedCrossRef
62.
A. Falorni, S. Chen, R. Zanchetta, L. Yu, C. Tiberti, M.L. Bacosi, J. Furmaniak, V. Bini, F. Dotta, G.S. Eisenbarth, B.R. Smith, C. Betterle, Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin. Immunol. 140, 291–299 (2011)PubMedCrossRef
63.
K. Lovas, E.S. Husebye, Replacement therapy in Addison’s disease. Expert Opin. Pharmacother. 4, 2145–2149 (2003)PubMedCrossRef
64.
65.
N.V. Esteban, T. Loughlin, A.L. Yergay, J.K. Zawadki, J.D. Booth, J.C. Winterer et al., Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. 72, 39–45 (1991)PubMedCrossRef
66.
H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johansson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)PubMedCrossRef
67.
R.M. Reynolds, P.M. Stewart, J.R. Seckl, P.L. Padfield, Assessing the HPA axis in patients with pituitary disease: a UK survey. Clin. Endocrinol. (Oxf) 64, 82–85 (2006)CrossRef
68.
C.M. Feek, J.G. Ratcliffe, J. Seth, C.E. Gray, A.D. Toft, W.J. Irvine, Patterns of plasma cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clin. Endocrinol. (Oxf.) 14, 451–458 (1981)CrossRef
69.
R.S. Scott, R.A. Donald, E.A. Espiner, Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin. Endocrinol. (Oxf.) 9, 571–576 (1978)CrossRef
70.
W. Jeffcoate, Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann. Clin. Biochem. 36(2), 151–157 (1999)PubMed
71.
S. Laureti, A. Falorni, F. Santeusanio, Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J. Endocrinol. Invest. 26, 1071–1075 (2003)PubMed
72.
W. Arlt, C. Rosenthal, S. Hahner, B. Allolio: Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin. Endocrinol. (Oxf.) 64, 384–389 (2006)
73.
P.M. Mah, R.C. Jenkins, A. Rostami-Hodjegan, J. Newell-Price, A. Doane et al., Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 61, 367–375 (2004)CrossRef
74.
A.W. Meikle, J.D. Stringham, M.G. Woodward, D.T. Bishop, Heritability of variation of plasma cortisol levels. Metabolism 37, 514–517 (1988)PubMedCrossRef
75.
A.L. Barbato, R.L. Landau, Serum cortisol appearance-disappearance in adrenal insufficiency after oral cortisone acetate. Acta Endocrinol. (Copenh.) 84, 600–604 (1977)
76.
R.W. Groves, G.C. Toms, B.J. Hougthon, J.P. Monson, Corticosteroid replacement therapy: twice or thrice daily? J.R.Soc.Med. 81, 514–516 (1988)PubMed
77.
L. Barbetta, C. Dall’Asta, T. Re, R. Libè, E. Costa, B. Ambrosi, Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J. Endocrinol. Invest. 28, 632–637 (2005)PubMed
78.
T.A. Howlett, An assessment of optimal hydrocortisone replacement therapy. Clin. Endocrinol. (Oxf.) 46, 263–268 (1997)CrossRef
79.
A.H. Thomson, M.C. Devers, A.M. Wallace, D. Grant, K. Campbell et al., Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 66, 789–796 (2007)CrossRef
80.
E. Charmandari, A. Johnston, C.G. Brook, P.C. Hindmarsh, Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Endocrinol. 169, 65–70 (2001)PubMedCrossRef
81.
B. Sauve, G. Koren, G. Walsh, S. Tokmakejian, S.H. Van Uum, Measurement of cortisol in human hair as a biomarker of systemic exposure. Clin. Invest. Med. 30, E183–E191 (2007)PubMed
82.
L.F. Hofman, Human saliva as a diagnostic specimen. J. Nutr. 131, 1621S–1625S (2001)PubMed
83.
A. Moreira, F. Arsati, de Oliveira Lima Arsati, Y.B., da Silva, D.A. de Araujo, V.C. Salivary cortisol in top-level professional soccer players. Eur. J. Appl. Physiol. 106, 25–30 (2009)PubMedCrossRef
84.
D. Riad-Fahmy, G.F. Read, R.F. Walker, Salivary steroid assays for assessing variation in endocrine activity. J. Steroid Biochem. 19, 265–272 (1983)PubMedCrossRef
85.
86.
I. Perogamvros, B.G. Keevil, D.W. Ray, P.J. Trainer, Salivary cortisone is a potential biomarker for serum free cortisol. J. Clin. Endocrinol. Metab. 95, 4951–4958 (2010)PubMedCrossRef
87.
L.D. Dorn, J.F. Lucke, T.L. Loucks, S.L. Berga, Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann. Clin. Biochem. 44, 281–284 (2007)PubMedCrossRef
88.
J.G. Lewis, Steroid analysis in saliva: an overview. Clin. Biochem. Rev. 27, 139–146 (2006)PubMed
89.
90.
J.W. Findling, H. Raff, Cushing’s Syndrome: important issues in diagnosis and management. J. Clin. Endocrinol. Metab. 91, 3746–3753 (2006)PubMedCrossRef
91.
H. Raff, Utility of salivary cortisol measurements in Cushing’s syndrome and adrenal insufficiency. J. Clin. Endocrinol. Metab. 94, 3647–3655 (2009)PubMedCrossRef
92.
H. Raff, Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming age. Endocrine 41, 353–354 (2012)PubMedCrossRef
93.
E.M. Scott, H.H. McGarrigle, G.C. Lachelin, The increase in plasma and saliva cortisol levels in pregnancy is not due to the increase in corticosteroid-binding globulin levels. J. Clin. Endocrinol. Metab. 71, 639–644 (1990)PubMedCrossRef
94.
A.M. Maguire, G.R. Ambler, B. Moore, M. McLean, M.G. Falleti, C.T. Cowell, Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. Pediatrics 120, e164–e171 (2007)PubMedCrossRef
95.
V. Wong, T. Yan, A. Donald, M. McLean, Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin. Endocrinol. (Oxf.) 61, 131–137 (2004)CrossRef
96.
K. Lovås, T.E. Thorsten, E.S. Husebye, Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease. J. Endocrinol. Invest. 29, 727–731 (2006)PubMed
97.
K. Lovås, E.S. Husebye, Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur. J. Endocrinol. 157, 109–112 (2007)PubMedCrossRef
98.
P. Restituto, J.C. Galofre, M.J. Gil, C. Mugueta, S. Santos et al., Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. Clin. Biochem. 41, 688–692 (2008)PubMedCrossRef
99.
E. Badrick, C. Kirschbaum, M. Kumari, A. Steptoe, K. O’Donnell, M. Marmot, The relationship between smokling status and cortisol secretion. J. Clin. Endocrinol. Metab. 92, 819–824 (2007)PubMedCrossRef
100.
A.M. Hansen, A.H. Garde, R. Persson, Sources of biological and methodological variation in salivary cortisol and their impact on measurement among healthy adults: a review. Scand. J. Clin. Lab. Invest. 68, 448–458 (2008)PubMedCrossRef
101.
J. Vialard-Miguel, N. Belaidi, L. Lembeye, J.B. Corcuff, Lemon juice alters cortisol assays in saliva. Clin. Endocrinol. (Oxf.) 63, 478–479 (2005)CrossRef
102.
M. Groschl, R. Wagner, M. Rauh, H.G. Dorr, Stability of salivary steroids: the influences of storage, food and dental care. Steroids 66, 737–741 (2001)PubMedCrossRef
103.
M.C. Garcia, A. de Souza, G.P. Bella, D.M. Grassi-Kassisse, A.P. Tacla, R.C. Sapadari-Bratfisch, Salivary cortisol levels in Brazilian citizens of distintc socioeconomic and cultural levels. Ann.N.Y.Acad.Sci. 1148, 504–508 (2008)PubMedCrossRef
104.
G.L. Brown, E.L. McGarvey, E.A. Schirtcliff, A. Keller, D.A. Granger, K. Flavin, Salivary cortisol, dehydroepiandrosterone, and testosterone interrelationships in healthy young males: a pilot study with implications for studies of aggressive behavior. Psychistry Res. 159, 67–76 (2008)CrossRef
105.
S. Hahner, M. Loeefler, B. Bleicken, C. Drechsler, D. Milovanovic, M. Fassnacht, M. Ventz, M. Quinkler, B. Allolio, Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 (2010)PubMedCrossRef
106.
K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162, 115–120 (2010)PubMedCrossRef
107.
A.J. Chakera, B. Vaidya, Addison’s disease in adults: diagnosis and management. Am. J. Medicine 123, 409–413 (2010)CrossRef
108.
W. Oelkers, Mineralocorticoid substitution in pregnant Addisonian women. J. Endocrinol. Invest. 27, 406 (2004)PubMed
109.
P. Methlie, E.E. Husebye, S. Hustad, E.A. Lien, K. Løvås, Grapefruit juice and licorice increase cortisol availability in patients with Addison’s disease. Eur. J. Endocrinol. 165, 761–769 (2011)PubMedCrossRef
110.
H. Cooper, B. Bhattacharya, V. Verma, A.J. McCulloch, W.S. Smellie, A.H. Heald, Liquorice and soy sauce, a life-saving concoction in a patient with Addison’s disease. Ann. Clin. Biochem. 44, 397–399 (2007)PubMedCrossRef
111.
B. Ambrosi, L. Barbetta, L. Morricone, Diagnosis and management of Addison’s disease during pregnancy. J. Endocrinol. Invest. 26, 698–702 (2003)PubMed
112.
E. Barrett-Connor, K.T. Khaw, S.S.C. Yen, A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N. Engl. J. Med. 315, 1519–1524 (1986)PubMedCrossRef
113.
P. Ebeling, V.A. Kiovisto, Physiological importance of dehydroepiandrosterone. Lancet 343, 1479–1481 (1994)PubMedCrossRef
114.
P. Sambrook, J. Birmingham, D. Champion, P. Kelly, S. Kempler, J. Freund, J. Eisman, Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. J. Rheumatol. 19, 357–361 (1992)PubMed
115.
R. Libè, L. Barbetta, C. Dall’Asta, F. Salvaggio, C. Gala, P. Beck-Peccoz, B. Ambrosi, Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J. Endocrinol. Invest. 27, 736–741 (2004)PubMed
116.
W. Arlt, F. Callies, J.C. van Vlijmen, I. Koehler, M. Reincke, M. Bidlingmaier, D. Huebler, M. Oettel, M. Ernst, H.M. Schulte, B. Allolio, Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 341, 1013–1020 (1999)PubMedCrossRef
117.
P.J. Hunt, E.M. Gurnell, F.A. Huppert, C. Richards, A.T. Prevost, J.A. Wass, J. Herbert, V.K. Chatterjee, Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 85, 4650–4656 (2000)PubMedCrossRef
118.
E.M. Gurnell, P.J. Hunt, S.E. Curran, C.L. Conway, E.M. Pullenayegum, F.A. Huppert, J.E. Compston, J. Herbert, V.K.K. Chatterjee, Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 93, 400–409 (2008)PubMedCrossRef
119.
R. Bergthorsdottir, M. Leonsson-Zachrisson, A. Odén, G. Johannsson, Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006)PubMedCrossRef
120.
S. Bensing, L. Brandt, F. Tabaroj, O. Sjöberg, B. Nilsson, A. Ekbom, P. Blomqvist, O. Kämpe, Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin. Endocrinol. (Oxf.) 69, 697–704 (2008)CrossRef
121.
M.M. Erichsen, K. Løvås, K.J. Fougner, J. Svartberg, E.R. Hauge, J. Bollerslev, J.P. Berg, B. Mella, E.S. Husebye, Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur. J. Endocrinol. 160, 233–237 (2009)PubMedCrossRef
122.
T. Rosén, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285–288 (1990)PubMedCrossRef
123.
J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Propsective Hypopituitary Study Group. Lancet 357, 425–431 (2001)PubMedCrossRef
124.
J.L. Mills, L.B. Schonberger, D.K. Wysowski, P. Brown, S.J. Durako, C. Cox, F. Kong, J.E. Fradkin, Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J. Pediatr. 144, 430–436 (2004)PubMedCrossRef
125.
W.H. Ettinger, H.F. Klinefelter, P.O. Kwiterovitch, Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 63, 167–172 (1987)PubMedCrossRef
126.
H.K. Choi, J.D. Seeger, Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 53, 528–535 (2005)PubMedCrossRef
127.
A.K. McDonough, J.R. Curtis, K.G. Saag, The epidemiology of glucocorticoid-associated adverse events. Curr. Opin. Rheumatol. 20, 131–137 (2008)PubMedCrossRef
128.
I. Karp, M. Abrahamowicz, P.R. Fortin, L. Pilote, C. Neville, C. Pineau et al., Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum. 59, 169–175 (2008)PubMedCrossRef
129.
D.H. van Raalte, D.M. Ouwens, M. Diamant, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur. J. Clin. Invest. 39, 81–93 (2009)PubMedCrossRef
130.
K. Walker-Bone, Recognizing and treating secondary osteoporosis. Nat. Rev. Rheumatol. 8, 480–492 (2012)PubMedCrossRef
131.
G.P. Rossi, T.M. Seccia, C. Maniero, A.C. Pessina, Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J. Hypertens. 29, 2295–2309 (2011)PubMedCrossRef
132.
J.L. Beaudry, M.C. Riddell, Effects of glucocorticoids and exercise on pancreatic β cell function and diabetes development. Diabetes Metab. Res. Rev. doi:10.​1002/​dmrr.​2310 (2012)
133.
M.N. Nanjee, N.E. Miller, Plasma lipoproteins and adrenocortical hormones in men—positive association of low density lipoprotein cholesterol with plasma cortisol concentration. Clin. Chim. Acta 180, 113–120 (1989)PubMedCrossRef
134.
K.A. al-Shoumer, K.H. Cox, C.L. Hughes, W. Richmond, D.G. Johnston, Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy. J.Clin.Endocrinol.Metab. 82, 2653–2659 (1997)PubMedCrossRef
135.
V. Markussis, S.A. Beshyah, C. Fisher, P. Sharp, A.N. Nicolaides, D.G. Johnston, Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340, 1188–1192 (1992)PubMedCrossRef
136.
R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinol. Invest. 32, 917–923 (2009)PubMed
137.
R. Giordano, S. Marzotti, R. Berardelli, I. Karamouzis, A. Brozzetti, V. D’Angelo, G. Mengozzi, G. Mandrile, D. Giachino, G. Migliaretti, V. Bini, A. Falorni, E. Ghigo, E. Arvat, BCLI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidemia in patients with Addison’s disease. Clin. Endocrinol. (Oxf.). doi:10.​1111/​j.​1365-2265.​2012.​04439.​x (2012)
138.
J.P. Devogelaer, J. Crabbé, C. Nagant de Deuxchaisnes, Bone mineral density in Addison’s disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. (Clin. Res. Ed.) 294, 798–800 (1987)
139.
P.M. Zelissen, R.J. Croughs, P.P. van Rijk, J.A. Raymakers, Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. 120, 207–210 (1994)PubMedCrossRef
140.
C.M. Florkowski, S.J. Holmes, J.R. Elliot, R.A. Donald, E.A. Espiner, Bone mineral density is reduced in female but not male subjects with Addison’s disease. N. Z. Med. J. 107, 52–53 (1994)PubMed
141.
M.A. Valero, M. Leon, M.P. Ruiz Valdepeñas, L. Larrodera, M.B. Lopez, K. Papapietro, A. Jara, F. Hawkins, Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner. 26, 9–17 (1994)PubMedCrossRef
142.
S.R. Peacey, C.Y. Guo, A.M. Robinson, A. Price, M.A. Giles, R. Eastell, A.P. Weetman, Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin. Endocrinol. (Oxf.) 46, 255–261 (1997)CrossRef
143.
G.D. Braatvedt, M. Joyce, M. Evans, J. Clearwater, I.R. Reid, Bone mineral density in patients with treated Addison’s disease. Osteoporos. Int. 10, 435–440 (1999)PubMedCrossRef
144.
E. Jódar, M.P. Valdepeñas, G. Martinez, A. Jara, F. Hawkins, Long-term follow-up of bone mineral density in Addison’s disease. Clin. Endocrinol. (Oxf.) 58, 617–620 (2003)CrossRef
145.
N. Chikada, T. Imaki, M. Hotta, K. Sato, K. Takano, An assessment of bone mineral density in patients with Addison’s disease and isolated ACTH deficiency treated with glucocorticoid. Endocr. J. 51, 355–360 (2004)PubMedCrossRef
146.
G. Bassotti, D. Di Sarra, D. Pietrobono, R. Schiaffini, T. Battocletti, T. D’Amico, P. Gargiulo, Polyglandular autoimmune endocrine insufficiency complicated by severe osteoporosis. Minerva Endocrinol. 31, 289–296 (2006)PubMed
147.
L. Leelarathna, L. Breen, J.K. Powrie, S.M. Thomas, R. Guzder, B. McGowan, P.V. Carroll, Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38, 113–117 (2010)PubMedCrossRef
148.
K. Løvås, C.G. Gjesdal, M. Christensen, A.B. Wolff, B. Almås, J. Svartberg, K.J. Fougner, U. Syversen, J. Bollerslev, J.A. Falch, P.J. Hunt, V.K. Chatterjee, E.S. Husebye, Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur. J. Endocrinol. 160, 993–1002 (2009)PubMedCrossRef
149.
S. Björnsdottir, M. Sääf, S. Bensing, O. Kämpe, K. Michaëlsson, J.F. Ludvigsson, Risk of hip fracture in Addison’s disease: a population-based cohort study. J. Intern. Med. 270, 187–195 (2011)PubMedCrossRef
150.
K.R. Koetz, M. Ventz, S. Diederich, M. Quinkler, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J. Clin. Endocrinol. Metab. 97, 85–92 (2012)PubMedCrossRef
151.
G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010)PubMedCrossRef
152.
K. Lovas, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease. Clin. Endocrinol. (Oxf.) 56, 581–588 (2002)CrossRef
153.
S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.C. Koschker, M. Quinkler et al., Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 (2007)PubMedCrossRef
154.
B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, B. Allolio, M. Quinkler, Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811–817 (2008)PubMedCrossRef
155.
K. Løvås, S. Curran, M. Oksnes, E.S. Husebye, F.A. Huppert, V.K. Chatterjee, Development of a disease-specific quality of life questionnaire in Addison’s disease. J. Clin. Endocrinol. Metab. 95, 545–551 (2010)PubMedCrossRef
156.
M. Øksnes, S. Bensing, A.L. Hulting, O. Kämpe, A. Hackemann, G. Meyer, K. Badenhoop, C. Betterle, A. Parolo, R. Giordano, A. Falorni, L. Papierska, W. Jeske, A.A. Kasperlik-Zaluska, V.K. Chatterjee, E.S. Husebye, K. Løvås, Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012)PubMedCrossRef
157.
M.F. Dallman, S.F. Akana, S. Bhatnagar, M.E. Bell, A.M. Strack, Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentrations. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), S40–S46 (2000)PubMedCrossRef
158.
M. Debono, C. Ghobadi, A. Rostami-Hodjegan, H. Huatan, M.J. Campbell, J. Newell-Price, K. Darzy, D.P. Merke, W. Arlt, R.J. Ross, Modified-release hydrocortisone to provide circadian cortisol profiles. J. Clin. Endocrinol. Metab. 94, 1548–1554 (2009)PubMedCrossRef
159.
S. Verma, C. Vanryzin, N. Sinaii, M.S. Kim, L.K. Nieman, S. Ravindran, K.A. Calis, W. Arlt, R.J. Ross, D.P. Merke, A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortysone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin. Endocrinol. (Oxf.) 72, 441–447 (2010)
160.
E.M. McConnell, P.M. Bell, C. Ennis, D.R. Hadden, D.R. McCance, B. Sheridan, A.B. Atkinson, Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clin. Endocrinol. (Oxf.) 56, 195–201 (2002)CrossRef
161.
D. Garcia-Borreguero, T.A. Wehr, O. Larrosa, J.J. Granizo, D. Hardwick, G.P. Chrousos, T.C. Friedman, Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 85, 4201–4206 (2000)PubMedCrossRef
162.
G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009)PubMedCrossRef
163.
G. Johansson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engstrom, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M.K. Biller, J.P. Monson, P.M. Stewart, H. Lennernas, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012)CrossRef
164.
A.J. Coles, S. Thompson, A.L. Cox, S. Curran, E.M. Gurnell, V.K. Chatterjee, Dehydroepiandrosterone replacement in patients with Addison’s disease has a bimodal effect on regulatory (CD4 + CD25hi and CD4 + FoxP3 +) T cells. Eur. J. Immunol. 35, 3694–3703 (2005)PubMedCrossRef
165.
S.H. Pearce, A.L. Mitchell, S. Bennett, P. King, S. Chandran, S. Nag, S. Chen, B.R. Smith, J.D. Isaacs, B. Vaidya, Adrenal steroidogenesis after b lymphocyte depletion therapy in new-onset Addison’s disease. J. Clin. Endocrinol. Metab. (2012). [Epub ahead of print]
166.
A. De Bellis, A. Falorni, S. Laureti et al., Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J. Clin. Endocrinol. Metab. 86, 675–678 (2001)CrossRef
Metadata
Title
Therapy of adrenal insufficiency: an update
Authors
Alberto Falorni
Viviana Minarelli
Silvia Morelli
Publication date
01-06-2013
Publisher
Springer US
Published in
Endocrine / Issue 3/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9835-4

Other articles of this Issue 3/2013

Endocrine 3/2013 Go to the issue

Meta-Analysis

Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis

Review

Pituitary metastasis of thyroid cancer

Original Article

Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique

Original Article

Low calorie and carbohydrate diet: to improve the cardiovascular risk indicators in overweight or obese adults with prediabetes

Original Article

Racial differences in adiponectin and leptin in healthy premenopausal women

Original Article

Resistance training decreases serum inflammatory markers in diabetic rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits